Yongjian Wu

BIOMARKER ANALYSES AND OVERALL SURVIVAL (OS) FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3, FASTACT-2 STUDY OF INTERCALATED ERLOTINIB WITH FIRST-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)

T. Mok, S. Thongprasert, B. Klughammer, 2012 .

OA10.07 Resistance Mechanisms of Osimertinib in Chinese Non-Small Cell Lung Cancer patients: Analysis from AURA17 Trial

Ying Cheng, He-long Zhang, Yuankai Shi, 2018, Journal of Thoracic Oncology.

P3.01-039 Sequential Afatinib-Osimertinib Therapy in EGFR Mutation-Positive (EGFRm+) NSCLC: Analysis of Time on Treatment and OS

L. Sequist, K. O'Byrne, T. Mok, 2017 .

PS02.20 Subsequent Therapies Post-Afatinib Among Patients with EGFR Mutation-Positive (EGFRm+) NSCLC in LUX-Lung 3, 6 and 7: Topic: Medical Oncology

L. Sequist, Wenbo Tang, L. Paz-Ares, 2017 .

P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

Ying Cheng, S. Ramalingam, M. Saggese, 2018, Journal of Thoracic Oncology.